GlobeNewsWire
24 Jun 2026, 10:35 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Eli Lilly & Company is participating in a $100 million equity offering for Absci Corporation. — Investment from a major pharmaceutical leader like Eli Lilly serves as a strong institutional validation of Absci's AI drug discovery platform.
+0.60Absci is pricing an underwritten offering of approximately 13.5 million shares at $7.41 per share. — Equity offerings typically cause immediate share price dilution for existing stockholders.
-0.30Net proceeds from the offering will be used to advance the ABS-201 anti-PRLR antibody program for androgenetic alopecia and endometriosis. — Provides clear funding for a specific clinical-stage pipeline, reducing short-term liquidity risk for these programs.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company successfully priced a $100 million offering to fund the advancement of its AI-designed antibody program.
Eli Lilly is participating as an investor in Absci's capital raise, signaling strategic interest in AI-driven drug discovery.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
GlobeNewsWire
12h ago
